Analyst consensus ratings, 12-month price targets, and expert recommendations for Xeris Biopharma Holdings, Inc. stock.
Investment consensus from 2 professional research analysts
Loading chart...
Recent analyst recommendations with rating changes and price target updates (last 90 days)
| Date | Analyst | Firm | Action | Rating | Price Target |
|---|---|---|---|---|---|
| Unknown Analyst | Oppenheimer | Reiterates | Buy | $18.00 | |
| Chase Knickerbocker | Craig-Hallum | Reiterates | Buy | $12.00 | |
| Chase Knickerbocker | Craig-Hallum | Maintains | Buy | - |
The analyst consensus rating for XERS is "Buy" based on 2 analyst recommendations.
The average 12-month price target for XERS is $15.00, representing an upside of 94.6% from the current price of $7.71.
Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.
A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.
